COVID-19 as a catalyst for reimagining cervical cancer prevention
Cervical cancer has killed millions of women over the past decade. In 2019 the World Health Organization launched the Cervical Cancer Elimination Strategy, which included ambitious targets for vaccination, screening, and treatment. The COVID-19 pandemic disrupted progress on the strategy, but lessons learned during the pandemic - especially in vaccination, self-administered testing, and coordinated mobilization on a global scale - may help with efforts to achieve its targets. However, we must also learn from the failure of the COVID-19 response to include adequate representation of global voices. Efforts to eliminate cervical cancer will only succeed if those countries most affected are involved from the very start of planning. In this article we summarize innovations and highlight missed opportunities in the COVID response, and make recommendations to leverage the COVID experience to accelerate the elimination of cervical cancer globally.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
eLife - 12(2023) vom: 18. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luckett, Rebecca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID19 |
|---|
| Anmerkungen: |
Date Completed 12.05.2023 Date Revised 14.05.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7554/eLife.86266 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355746409 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355746409 | ||
| 003 | DE-627 | ||
| 005 | 20231226065009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7554/eLife.86266 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355746409 | ||
| 035 | |a (NLM)37070731 | ||
| 035 | |a (PII)e86266 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luckett, Rebecca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 as a catalyst for reimagining cervical cancer prevention |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2023 | ||
| 500 | |a Date Revised 14.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Cervical cancer has killed millions of women over the past decade. In 2019 the World Health Organization launched the Cervical Cancer Elimination Strategy, which included ambitious targets for vaccination, screening, and treatment. The COVID-19 pandemic disrupted progress on the strategy, but lessons learned during the pandemic - especially in vaccination, self-administered testing, and coordinated mobilization on a global scale - may help with efforts to achieve its targets. However, we must also learn from the failure of the COVID-19 response to include adequate representation of global voices. Efforts to eliminate cervical cancer will only succeed if those countries most affected are involved from the very start of planning. In this article we summarize innovations and highlight missed opportunities in the COVID response, and make recommendations to leverage the COVID experience to accelerate the elimination of cervical cancer globally | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a COVID19 | |
| 650 | 4 | |a HPV | |
| 650 | 4 | |a cervical cancer | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a global health | |
| 650 | 4 | |a global policy | |
| 650 | 4 | |a none | |
| 650 | 4 | |a prevention | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Feldman, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Yin Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Moscicki, Anna-Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliano, Anna R |e verfasserin |4 aut | |
| 700 | 1 | |a de Sanjosé, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Andreas M |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Shuk On Annie |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatla, Neerja |e verfasserin |4 aut | |
| 700 | 1 | |a Stanley, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Brotherton, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Palefsky, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Garland, Suzanne |e verfasserin |4 aut | |
| 700 | 0 | |a International Papillomavirus Society (IPVS) Policy Committee |e verfasserin |4 aut | |
| 700 | 1 | |a On Behalf Of The International Papillomavirus Society Ipvs Policy Committee |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t eLife |d 2012 |g 12(2023) vom: 18. Apr. |w (DE-627)NLM221831460 |x 2050-084X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g day:18 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7554/eLife.86266 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |b 18 |c 04 | ||